Global (United States, European Union and China) Organ Preservation Solutions Market Research Report 2019-2025

2 Global Organ Preservation Solutions Quarterly Market Size Analysis

• 2.1 Organ Preservation Solutions Business Impact Assessment - COVID-19
  • 2.1.1 Global Organ Preservation Solutions Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
• 2.2 Global Organ Preservation Solutions Quarterly Market Size 2020-2021
• 2.3 COVID-19-Driven Market Dynamics and Factor Analysis
  • 2.3.1 Drivers
  • 2.3.2 Restraints
  • 2.3.3 Opportunities
  • 2.3.4 Challenges

3 Quarterly Competitive Assessment, 2020

• 3.1 By Players, Global Organ Preservation Solutions Quarterly Market Size, 2019 VS 2020
• 3.2 By Players, Organ Preservation Solutions Headquarters and Area Served
• 3.3 Date of Key Players Enter into Organ Preservation Solutions Market
• 3.4 Key Players Organ Preservation Solutions Product Offered
• 3.5 Mergers & Acquisitions, Expansion Plans

4 Impact of Covid-19 on Organ Preservation Solutions Segments, By Type

• 4.1 Introduction
  • 1.4.1 Viaspan
  • 1.4.2 Custodial
  • 1.4.3 Renograf
  • 1.4.4 Hypothermosol
  • 1.4.5 Perfadex
  • 1.4.6 Lifor
  • 1.4.7 HBS Solution
  • 1.4.8 siRNA Transplant Solutions
  • 1.4.9 Others
• 4.2 By Type, Global Organ Preservation Solutions Market Size, 2019-2021

5 Impact of Covid-19 on Organ Preservation Solutions Segments, By Application

• 5.1 Overview
  • 5.5.1 Hypothermic Perfusion Preservation (HPP)
  • 5.5.2 Static Cold Storage (SCS)
  • 5.5.3 Others
• 5.2 By Application, Global Organ Preservation Solutions Market Size, 2019-2021
  • 5.2.1 By Application, Global Organ Preservation Solutions Market Size by Application, 2019-2021

6 Geographic Analysis

• 6.1 Introduction
• 6.2 North America
  • 6.2.1 Macroeconomic Indicators of US
  • 6.2.2 US
  • 6.2.3 Canada
• 6.3 Europe
  • 6.3.1 Macroeconomic Indicators of Europe
  • 6.3.2 Germany
  • 6.3.3 France
  • 6.3.4 UK
  • 6.3.5 Italy
• 6.4 Asia-Pacific
  • 6.4.1 Macroeconomic Indicators of Asia-Pacific
  • 6.4.2 China
  • 6.4.3 Japan
  • 6.4.4 South Korea
  • 6.4.5 India
  • 6.4.6 ASEAN
• 6.5 Rest of World
  • 6.5.1 Latin America
  • 6.5.2 Middle East and Africa

7 Company Profiles

• 7.1 Dr. Franz Köhler Chemie
  • 7.1.1 Dr. Franz Köhler Chemie Business Overview
  • 7.1.2 Dr. Franz Köhler Chemie Organ Preservation Solutions Quarterly Revenue, 2020
  • 7.1.3 Dr. Franz Köhler Chemie Organ Preservation Solutions Product Introduction
  • 7.1.4 Dr. Franz Köhler Chemie Response to COVID-19 and Related Developments
• 7.2 Teva Pharmaceutical Industries Ltd.
  • 7.2.1 Teva Pharmaceutical Industries Ltd. Business Overview
  • 7.2.2 Teva Pharmaceutical Industries Ltd. Organ Preservation Solutions Quarterly Revenue, 2020
  • 7.2.3 Teva Pharmaceutical Industries Ltd. Organ Preservation Solutions Product Introduction
  • 7.2.4 Teva Pharmaceutical Industries Ltd. Response to COVID-19 and Related Developments
• 7.3 Lifeline Scientific
  • 7.3.1 Lifeline Scientific Business Overview
  • 7.3.2 Lifeline Scientific Organ Preservation Solutions Quarterly Revenue, 2020
  • 7.3.3 Lifeline Scientific Organ Preservation Solutions Product Introduction
  • 7.3.4 Lifeline Scientific Response to COVID-19 and Related Developments
• 7.4 Bristol-Myers Squibb
  • 7.4.1 Bristol-Myers Squibb Business Overview
  • 7.4.2 Bristol-Myers Squibb Organ Preservation Solutions Quarterly Revenue, 2020
  • 7.4.3 Bristol-Myers Squibb Organ Preservation Solutions Product Introduction
  • 7.4.4 Bristol-Myers Squibb Response to COVID-19 and Related Developments
• 7.5 BioLife Solutions, Inc.
  • 7.5.1 BioLife Solutions, Inc. Business Overview
  • 7.5.2 BioLife Solutions, Inc. Organ Preservation Solutions Quarterly Revenue, 2020
  • 7.5.3 BioLife Solutions, Inc. Organ Preservation Solutions Product Introduction
  • 7.5.4 BioLife Solutions, Inc. Response to COVID-19 and Related Developments
• 7.6 XVIVO Perfusion AB
  • 7.6.1 XVIVO Perfusion AB Business Overview
  • 7.6.2 XVIVO Perfusion AB Organ Preservation Solutions Quarterly Revenue, 2020
  • 7.6.3 XVIVO Perfusion AB Organ Preservation Solutions Product Introduction
  • 7.6.4 XVIVO Perfusion AB Response to COVID-19 and Related Developments
• 7.7 ToleroTech, Inc
  • 7.7.1 ToleroTech, Inc Business Overview
  • 7.7.2 ToleroTech, Inc Organ Preservation Solutions Quarterly Revenue, 2020
  • 7.7.3 ToleroTech, Inc Organ Preservation Solutions Product Introduction
  • 7.7.4 ToleroTech, Inc Response to COVID-19 and Related Developments
• 7.8 CryoLife, Inc.
  • 7.8.1 CryoLife, Inc. Business Overview
  • 7.8.2 CryoLife, Inc. Organ Preservation Solutions Quarterly Revenue, 2020
  • 7.8.3 CryoLife, Inc. Organ Preservation Solutions Product Introduction
  • 7.8.4 CryoLife, Inc. Response to COVID-19 and Related Developments
• 7.9 Claris Lifesciences Limited
  • 7.9.1 Claris Lifesciences Limited Business Overview
  • 7.9.2 Claris Lifesciences Limited Organ Preservation Solutions Quarterly Revenue, 2020
  • 7.9.3 Claris Lifesciences Limited Organ Preservation Solutions Product Introduction
  • 7.9.4 Claris Lifesciences Limited Response to COVID-19 and Related Developments
• 7.10 BioTime, Inc.
  • 7.10.1 BioTime, Inc. Business Overview
  • 7.10.2 BioTime, Inc. Organ Preservation Solutions Quarterly Revenue, 2020
  • 7.10.3 BioTime, Inc. Organ Preservation Solutions Product Introduction
  • 7.10.4 BioTime, Inc. Response to COVID-19 and Related Developments
• 7.11 21st Century Medicine
  • 7.11.1 21st Century Medicine Business Overview
  • 7.11.2 21st Century Medicine Organ Preservation Solutions Quarterly Revenue, 2020
  • 7.11.3 21st Century Medicine Organ Preservation Solutions Product Introduction
  • 7.11.4 21st Century Medicine Response to COVID-19 and Related Developments

8 Key Findings

9 Appendix

• 9.1 About US